Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.

International journal of cancer - 15 Feb 2007

Hayes Vanessa M, Severi Gianluca, Padilla Emma J D, Morris Howard A, Tilley Wayne D, Southey Melissa C, English Dallas R, Sutherland Robert L, Hopper John L, Boyle Peter, Giles Graham G

Abstract excerpt

Controversy exists over the significance of associations between the SRD5A2 (5alpha-reductase type 2) polymorphisms, A49T and V89L, and risk of prostate cancer. These potentially functional polymorphisms may alter life-long exposure to androgens with subsequent effects on male health and aging. The aim of this study was to examine the association of these variants with prostate cancer risk, plasma hormone levels...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Share to Alopecia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Androgens

Share to Case-Control Studies

Share to Incidence

Share to Population Surveillance

Share to Prostatic Neoplasms

Share to Risk Factors

Source

Identifiers

PMID: 17136762
DOI: 10.1002/ijc.22408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.PMID 17136762Read ↗

Steroid 5-{alpha}-reductase Type 2 (SRD5a2) gene polymorphisms and risk of prostate cancer: a HuGE review.Semantic proximity Read ↗

SRD5A2 gene polymorphisms and the risk of benign prostatic hyperplasia but not prostate cancer.Semantic proximity Read ↗

Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.Semantic proximity Read ↗

Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.Semantic proximity Read ↗

SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis.Semantic proximity Read ↗

Editorial comment on: Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.Semantic proximity Read ↗

The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population.Semantic proximity Read ↗

Association among polymorphisms in the steroid 5alpha-reductase type II (SRD5A2) gene, prostate cancer risk, and pathologic characteristics of prostate tumors in an Ecuadorian population.Semantic proximity Read ↗

Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.Semantic proximity Read ↗

Pharmacogenetics of human androgens and prostatic diseases.Semantic proximity Read ↗

A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase.Semantic proximity Read ↗

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.